In two phase 2 trials, the gene therapy ixoberogene soroparvovec (ixo-vec) was well tolerated and reduced the number of anti-vascular endothelial growth factor (VEGF) injections that patients with wet age-related macular degeneration needed, according to data presented at the American Society of Retina Specialists (ASRS) annual meeting being held in Long Beach, California.

Based on results from OPTIC and LUNA trials, ARTEMIS, the first of two pivotal phase 3 trials, has been designed to evaluate the efficacy and safety of a one-time intravitreal injection of ixo-vec compared with Eylea (aflibercept) 2 mg in patients with wet AMD.

Developed by Adverum Biotechnologies, ixo-vec is a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence. Aflibercept inhibits VEGF and is

See Full Page